ClinicalTrials.gg
CompletedNCT01249131Updated Aug 15, 2017Results posted

A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants

A Phase 1 interventional study of Cobimetinib in Healthy Volunteers, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will be an open-label, randomized, 3-way, 6-sequence crossover study in healthy participants for determining the relative bioavailability of the tablet formulation to the capsule formulation and the effect of food on the relative bioavailability of the tablet formulation.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Within range 18.5 to 29.9 kilograms per meter square (kg/m\^2)
  • In good health, determined by no findings from medical history, 12-lead (ECG) and vital signs
  • Clinical laboratory evaluations within the reference range for the test laboratory
  • Negative test for selected drugs of abuse at Screening and at each Check-in
  • Negative hepatitis panel and anti- virus and negative (HIV) antibody screens
  • Healthy males and females of non- or who agree to use effective

Exclusion criteria

Exclusion Criteria

  • Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy, hernia repair, and cholecystectomy will be allowed
  • History or presence of an abnormal
  • History of alcoholism or drug addiction prior to study start
  • Use of any tobacco-containing or nicotine-containing products prior to study start
  • Participation in any other study drug trial in which receipt of an investigational study drug occurred within 28 days or 5 half-lives, whichever is longer, prior to study start
  • Use of any prescription medications/products, including proton pump inhibitors, within 14 days prior to study start
  • Poor peripheral venous access
  • Any acute or chronic condition that would limit the participant's ability to complete and/or participate in this clinical study
  • Female participant is pregnant, lactating, or breastfeeding
  • Predisposing factors to retinal vein occlusion (RVO)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment A first, then Treatment B, followed by Treatment C

    Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.

    Drug: Cobimetinib

  • Experimental
    Treatment A first, then Treatment C, followed by Treatment B

    Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.

    Drug: Cobimetinib

  • Experimental
    Treatment B first, then Treatment A, followed by Treatment C

    Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.

    Drug: Cobimetinib

  • Experimental
    Treatment B first, then Treatment C, followed by Treatment A

    Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.

    Drug: Cobimetinib

  • Experimental
    Treatment C first, then Treatment A, followed by Treatment B

    Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.

    Drug: Cobimetinib

  • Experimental
    Treatment C first, then Treatment B, followed by Treatment A

    Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.

    Drug: Cobimetinib

Interventions

  • Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.

    Also known as: GDC-0973, XL518

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

    AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).

    Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose

  3. Minimum Observed Plasma Concentration (Cmin)

    Time frame: Day 1 at 0 hour (predose)

  4. Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose

  5. Apparent Volume of Distribution (V/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose

07

Results

Posted Jul 18, 2016

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment BTreatment B First, Then Treatment A, Followed by Treatment CTreatment B First, Then Treatment C, Followed by Treatment ATreatment C First, Then Treatment A, Followed by Treatment BTreatment C First, Then Treatment B, Followed by Treatment A
Started334334
Completed334334
Not completed000000
Washout Period of 10 Days
Participant flow — Washout Period of 10 Days
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment BTreatment B First, Then Treatment A, Followed by Treatment CTreatment B First, Then Treatment C, Followed by Treatment ATreatment C First, Then Treatment A, Followed by Treatment BTreatment C First, Then Treatment B, Followed by Treatment A
Started334334
Completed334324
Not completed000010
Withdrew: Adverse event000010
Second Intervention
Participant flow — Second Intervention
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment BTreatment B First, Then Treatment A, Followed by Treatment CTreatment B First, Then Treatment C, Followed by Treatment ATreatment C First, Then Treatment A, Followed by Treatment BTreatment C First, Then Treatment B, Followed by Treatment A
Started334324
Completed334324
Not completed000000
Washout Period of 10 Days
Participant flow — Washout Period of 10 Days
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment BTreatment B First, Then Treatment A, Followed by Treatment CTreatment B First, Then Treatment C, Followed by Treatment ATreatment C First, Then Treatment A, Followed by Treatment BTreatment C First, Then Treatment B, Followed by Treatment A
Started334324
Completed334324
Not completed000000
Third Intervention
Participant flow — Third Intervention
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment BTreatment B First, Then Treatment A, Followed by Treatment CTreatment B First, Then Treatment C, Followed by Treatment ATreatment C First, Then Treatment A, Followed by Treatment BTreatment C First, Then Treatment B, Followed by Treatment A
Started334324
Completed334324
Not completed000000

Outcome measures

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).

Time frame:
Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Reported as:
Geometric mean · nanograms*hours/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
nanograms*hours/milliliter (ng*hr/mL)Cobimetinib One 20 mg Tablet [Fasted]Cobimetinib Four 5 mg Capsules [Fasted]Cobimetinib One 20 mg Tablet [Fed]
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)780 ± 34.7717 ± 45.1858 ± 42.4
Statistical analysis
  • Cobimetinib One 20 mg Tablet [Fasted] vs Cobimetinib Four 5 mg Capsules [Fasted] · Ratio of least squares (ls) means (in %): 94.7 · 90% CI 83.9 to 107LS mean was calculated from analysis of variance (ANOVA). Data for dose-normalized AUCinf were natural log-transformed prior to analysis. Ratio of AUCinf LS means for log-transformed parameter (expressed as a percent).
  • Cobimetinib One 20 mg Tablet [Fasted] vs Cobimetinib One 20 mg Tablet [Fed] · Ratio of ls means (in %): 110 · 90% CI 98.2 to 124LS mean was calculated from ANOVA. Data for dose-normalized AUCinf were natural log-transformed prior to analysis. Ratio of AUCinf LS means for log-transformed parameter (expressed as a percent).
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax)
nanograms per milliliter (ng/mL)Cobimetinib One 20 mg Tablet [Fasted]Cobimetinib Four 5 mg Capsules [Fasted]Cobimetinib One 20 mg Tablet [Fed]
Maximum Observed Plasma Concentration (Cmax)16.0 ± 33.514.9 ± 45.917.2 ± 43.1
Statistical analysis
  • Cobimetinib One 20 mg Tablet [Fasted] vs Cobimetinib Four 5 mg Capsules [Fasted] · Ratio of ls means (in %): 96.9 · 90% CI 84.2 to 111LS mean was calculated from ANOVA. Data for dose-normalized Cmax were natural log-transformed prior to analysis. Ratio of Cmax LS means for log-transformed parameter (expressed as a percent).
  • Cobimetinib One 20 mg Tablet [Fasted] vs Cobimetinib One 20 mg Tablet [Fed] · Ratio of ls means (in %): 107 · 90% CI 93.8 to 123LS mean was calculated from ANOVA. Data for dose-normalized Cmax were natural log-transformed prior to analysis. Ratio of Cmax LS means for log-transformed parameter (expressed as a percent).
PrimaryMinimum Observed Plasma Concentration (Cmin)
Time frame:
Day 1 at 0 hour (predose)
Reported as:
Geometric mean · ng/mL
Minimum Observed Plasma Concentration (Cmin)
ng/mLCobimetinib One 20 mg Tablet [Fasted]Cobimetinib Four 5 mg Capsules [Fasted]Cobimetinib One 20 mg Tablet [Fed]
Minimum Observed Plasma Concentration (Cmin)0.307 ± 46.60.36 ± 56.60.361 ± 60.3
PrimaryApparent Oral Clearance (CL/F)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Reported as:
Geometric mean · Liters per hour (L/hr)
Apparent Oral Clearance (CL/F)
Liters per hour (L/hr)Cobimetinib One 20 mg Tablet [Fasted]Cobimetinib Four 5 mg Capsules [Fasted]Cobimetinib One 20 mg Tablet [Fed]
Apparent Oral Clearance (CL/F)25.6 ± 34.725.2 ± 45.123.3 ± 42.4
PrimaryApparent Volume of Distribution (V/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Reported as:
Geometric mean · Liters (L)
Apparent Volume of Distribution (V/F)
Liters (L)Cobimetinib One 20 mg Tablet [Fasted]Cobimetinib Four 5 mg Capsules [Fasted]Cobimetinib One 20 mg Tablet [Fed]
Apparent Volume of Distribution (V/F)2103 ± 40.41930 ± 50.21900 ± 38.3

Adverse events

Collected over Adverse events were recorded from start of study treatment in first period to end of last period (up to 30 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cobimetinib One 20 mg Tablet [Fasted]—0/19 (0%)6/19 (31.6%)
Cobimetinib Four 5 mg Capsules [Fasted]—0/19 (0%)9/19 (47.4%)
Cobimetinib One 20 mg Tablet [Fed]—0/20 (0%)8/20 (40%)
Most frequent other events
Showing 10 of 43
Most frequent other events
EventCobimetinib One 20 mg Tablet [Fasted]Cobimetinib Four 5 mg Capsules [Fasted]Cobimetinib One 20 mg Tablet [Fed]
NauseaGastrointestinal disorders1/192/191/20
VomitingGastrointestinal disorders0/192/190/20
Back painMusculoskeletal and connective tissue disorders0/192/190/20
Dry skinSkin and subcutaneous tissue disorders0/192/190/20
HeadacheNervous system disorders2/192/192/20
Abdominal discomfortGastrointestinal disorders0/191/192/20
DiarrhoeaGastrointestinal disorders0/191/191/20
DysphagiaGastrointestinal disorders1/190/191/20
Abdominal pain upperGastrointestinal disorders0/191/190/20
Faecal incontinenceGastrointestinal disorders0/191/190/20

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean36 (19 to 52)
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female7
Male13
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2010 to primary completion in Jan 2011, 1 month.

Results were first posted in Jul 2016, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2010
First posted
Nov 29, 2010
StartActual
Dec 1, 2010
Primary completionActual
Jan 10, 2011
CompletionActual
Jan 10, 2011
Results first posted
Jul 18, 2016
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01249131
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 29, 2010
Start date
Dec 1, 2010
Primary completion
Jan 10, 2011
Completion
Jan 10, 2011
Results posted
Jul 18, 2016
Last update
Aug 15, 2017

Study contacts

Isabelle Rooney, M.D., PhD
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion